Harrow Health Inc's stock experienced a 24-hour plunge of 10.62% in post-market trading, reflecting a sharp sell-off following the release of its latest financial results.

The decline was driven by the company's disappointing first-quarter 2026 performance, where revenue fell significantly short of analyst expectations. Harrow reported revenue of $44.2 million, missing the consensus estimate of $52.4 million, partly due to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Furthermore, the company's loss per share widened to $0.74, worse than the anticipated loss, and its gross margin contracted to 61% from 68% a year earlier.

Despite the quarterly setback, management reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million and projected an improvement in the second quarter. However, the immediate reaction from investors was negative, focusing on the earnings and revenue miss as well as the pressure on profitability.